Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 3, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023, and to provide a business overview.

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

ACM Research

Rocky Brands

Tsakos Energy Navigation Limited

Vital Energy Inc

Zymeworks Inc

When dealing with the best small-cap stocks to buy, investors effectively absorb higher risk for the possibility of substantive rewards. Even better, these rewards can come in quickly, enabling those seeking a boost in their portfolio to make up for lost ground.

7 Small-Cap Stocks to Buy Before the Breakout

BioNTech SE

Celularity

Innoviva

Regeneron Pharmaceuticals

Voyager Therapeutics

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors.

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, has a potentially large market, and sells for less than net cash on its balance sheet. An updated investment analysis on Chimerix, Inc. follows in the paragraphs below.

Chimerix: A High-Risk 'Lottery Ticket'

HF Sinclair Corp

Sanmina-SCI

Peabody Energy

PCTEL

Typically, securities may be less appreciated by the market because they stink, which means several proposals for best undervalued growth stocks for June might not make the cut. At the same time, betting on the same ship as everyone else presents its own risks.

7 Deeply Undervalued Growth Stocks to Buy in June

The biotechnology firm Chimerix has a high probability of success in its ongoing clinical trial in the treatment of pediatric brain tumors, according to analysts at Baird.  The firm initiated coverage of the North Carolina-based company with an Outperform rating and a $7 price target.

Chimerix's trial treating pediatric brain tumors has a 'relatively high' chance of success

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Allen Melemed - Chief Medical Officer Mike Andriole - Chief Financial and Business Officer Josh Allen - Chief Technology Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Securities Ed White - H.C. Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2023 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript

Chimerix (CMRX) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.28 per share a year ago.

Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates

– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 –

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 4, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business overview.

Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients

Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

AbCellera Biologics

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Point Biopharma Global

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Chimerix (CMRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Chimerix took quite a skid as it passed into the danger zone. Earnings for Q4, 2022 support an ongoing bull thesis for Chimerix.

Chimerix: Gaining Traction, Cash Runway To 2027

Aptevo Therapeutics

Beam Therapeutics

Dynavax Technologies

iTeos Therapeutics, Inc.

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

Chimerix, Inc. (NASDAQ:CMRX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Josh Allen - Chief Technology Officer of Imipridones Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Joseph Thome - TD Cowen Naureen Quibria - Capital One Securities Soumit Roy - Jones Research Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year-End 2022 Earnings Conference Call. I would now like to introduce your host for today's call Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix.

Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript

- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

AdTheorent Holding Company Inc

Alpha Metallurgical Resources

A-Mark Precious Metals

International Money Express Inc.

Silicon Motion Technology

Sensus Healthcare

With thousands of publicly traded companies to choose from, it's inevitable that a few will make the rounds of overlooked value stocks. These enterprises represent businesses that trade at an attractive multiple to a key financial.

7 Overlooked Value Stocks That Could Outperform the Market

Genfit - ADR

Harmony Biosciences Holdings

Selecta Biosciences

Vertex Pharmaceuticals

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

Moderna

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans

News for Chimerix Stock (CMRX)